BioLineRx, Ltd. - BioLine Innovations Jerusalem We are a clinical-stage, publicly-traded, (NASDAQ/ TASE: BLRX) biopharmaceutical development company based in Jerusalem, Israel. The Company's declared aim is to develop products suitable for today's pharmaceutical market satisfying an unmet medical need or exhibiting features and benefits above those of current therapies. Our close ties to technology transfer offices, research institutes, academic institutions and biotechnology companies, both in Israel and around the world, enable access to promising compounds at an early stage. The Company's scientists and experts in pharmacy and regulation, clinical trials and IP work together to advance promising drug candidates, supported and assisted by our distinguished panel of scientific advisers. In this manner the project quickly reaches successful fruition- partnerships with pharmaceutical companies for the final stages of clinical development and commercialization. Our business model involves three stages- "Bench to Bedside to Partner". The first stage involves a stringent selection process. Our expert team is particularly specialized at evaluating potential drug candidates from both scientific and marketing perspectives. Next, the copmany performs development through Phase II proof of concept studies. Finally, the company partners with pharmaceutical companies to complete the clinical development and bring the product to market. It also operates BioLine Innovations Jerusalem (BIJ) a biotechnology incubator to evaluate and develop pre-clinical therapeutic candidates, and an Early Development Program (EDP) dedicated to identifying and advancing promising early stage programs.